Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
42,194,093
-
Total 13F shares
-
21,435,682
-
Share change
-
+1,377,761
-
Total reported value
-
$387,312,097
-
Put/Call ratio
-
20%
-
Price per share
-
$18.07
-
Number of holders
-
92
-
Value change
-
+$39,178,138
-
Number of buys
-
63
-
Number of sells
-
22
Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) as of Q2 2023
As of 30 Jun 2023 Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) had 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 21,435,682 shares of stock of the company.
Largest 10 holders included RTW INVESTMENTS, LP, Vivo Capital, LLC, BlackRock Inc., COWEN AND COMPANY, LLC, Frazier Life Sciences Management, L.P., TANG CAPITAL MANAGEMENT LLC, Cormorant Asset Management, LP, PERCEPTIVE ADVISORS LLC, VANGUARD GROUP INC, and GEODE CAPITAL MANAGEMENT, LLC.
This table shows 92 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.